14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CRBP vs FGEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, FibroGen, Inc (FGEN) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CRBP carries a Unified Composite Score of 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin), whereas FGEN carries 61.2/100 (BUY) at $9.71 (61.4x Forward P/E, -499.1% operating margin).
Technical & Structure Timing Caution: CRBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3); meanwhile FGEN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 59.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRBP vs FGEN. Trailing 12-month operating profitability (CRBP 0.0% vs FGEN -499.1%) and valuation multiples (CRBP N/M vs FGEN 61.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $36.5M market capitalization and -499.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CRBP vs FGEN Key Questions & Quantitative Answers
As of Nov 16, 2026, FibroGen, Inc (FGEN) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CRBP carries a Unified Composite Score of 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin), whereas FGEN carries 61.2/100 (BUY) at $9.71 (61.4x Forward P/E, -499.1% operating margin). Technical & Structure Timing Caution: CRBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3); meanwhile FGEN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 59.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FGEN leads the Growth & Scale pillar: CRBP posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FGEN at +774.8% YoY revenue growth and +53.6% YoY earnings growth on $8.3M TTM revenue (N/A gross margin, -499.1% operating margin). On trailing 12-month operating scale, CRBP generates N/A in USD-normalized revenue versus $8.3M for FGEN. In operating R&D and SG&A reinvestment, CRBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FGEN.
FGEN screens cheaper on headline valuation multiples. CRBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FGEN trades at 61.4x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRBP (-131.5% ROE) versus FGEN (-1015.8% ROE) capital efficiency.
In options market volatility and institutional positioning, CRBP carries 197.6% implied volatility (66th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.93β · 121% Vol realized risk). By comparison, FGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.79β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.